Access to Antihypertensive Drugs in China

Circulation. 2018 Oct 23;138(17):1777-1779. doi: 10.1161/CIRCULATIONAHA.118.033360.

Authors

Ge Bai¹, Catherine Bennet², Jiguang Wang³, Gerard F Anderson⁴

Affiliations

¹ The Johns Hopkins Carey Business School, Washington, DC (B.G.).
² The Johns Hopkins School of Medicine, Baltimore, MD (C.B.).
³ Shanghai Jiao Tong University School of Medicine, China (J.W.).
⁴ The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (G.F.A.).

PMID: 30354658
DOI: 10.1161/CIRCULATIONAHA.118.033360

No abstract available

Keywords: China; antihypertensive agents; cardiovascular diseases; drug costs; hypertension.

MeSH terms

Antihypertensive Agents / economics*
Antihypertensive Agents / supply & distribution
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects
China / epidemiology
Drug Costs*
Drugs, Essential / economics*
Drugs, Essential / supply & distribution
Drugs, Essential / therapeutic use*
Health Expenditures*
Health Services Accessibility / economics*
Health Services Needs and Demand / economics
Humans
Hypertension / drug therapy*
Hypertension / economics*
Hypertension / epidemiology
Hypertension / physiopathology
Medication Adherence

Substances

Antihypertensive Agents
Drugs, Essential